Azitra Inc (AZTR) - Total Liabilities
Based on the latest financial reports, Azitra Inc (AZTR) has total liabilities worth $1.22 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Azitra Inc generate cash to assess how effectively this company generates cash.
Azitra Inc - Total Liabilities Trend (2021–2025)
This chart illustrates how Azitra Inc's total liabilities have evolved over time, based on quarterly financial data. Check AZTR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Azitra Inc Competitors by Total Liabilities
The table below lists competitors of Azitra Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Li Bang International Corporation Inc. Ordinary Shares
NASDAQ:LBGJ
|
USA | $20.02 Million |
|
EQTEC plc
LSE:EQT
|
UK | £9.22 Million |
|
Raja Ferry Port Public Company Limited
BK:RP
|
Thailand | ฿613.87 Million |
|
STS Global Income & Growth Trust PLC
LSE:STS
|
UK | GBX15.59 Million |
|
De La Rue PLC
LSE:DLAR
|
UK | GBX298.90 Million |
|
The Biotech Growth Trust PLC
LSE:BIOG
|
UK | GBX32.10 Million |
|
Harfang Exploration Inc
V:HAR
|
Canada | CA$281.96K |
|
Tree House Education & Accessories Limited
NSE:TREEHOUSE
|
India | Rs48.40 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Azitra Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Azitra Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Azitra Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Azitra Inc (2021–2025)
The table below shows the annual total liabilities of Azitra Inc from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.22 Billion | +73621.95% |
| 2024-12-31 | $1.66 Million | -24.60% |
| 2023-12-31 | $2.20 Million | -94.93% |
| 2022-12-31 | $43.43 Million | +20.74% |
| 2021-12-31 | $35.97 Million | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more